Access in all areas? A round-up of developments in market access and health technology assessment: part 12
{{output}}
In this update we cover the impacts of the US Most Favored Nation pricing policy and research evaluating drug availability and affordability in China as a result of the National Reimbursement Drug List negotiation policy. ... ...
